Venclexta (Venetoclax) Patent Expiration, LOE Window & CMS Spending

Venclexta (Venetoclax) by AbbVie: FDA Orange Book core substance LOE 2032-01-29 (last listed 2033-09-06), 1 AB generics, $984.8M 2024 CMS Part D & Medicaid spend, and 24 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAbbVie
FDA Application & PathwayN208573 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2032-01-29
Last Listed Patent or Exclusivity Date2033-09-06
Orange Book Patents (*PED Extensions)10 patents (0 *PED)
Active AB-Rated Generic Competitors1
2024 CMS Total Public Spend$984.8M
2024 Medicare Part D Spend$941.7M
2024 Medicaid Spend$43.1M
Reported Wholesale Price Change (CA SB 17)24 WAC filings (max 20.3% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AbbVie across sibling Meru public-data platforms.